Off-label uses of Sorafenib and Sunitinib
BlueCross BlueShield Association
Record ID 32010000210
English
Authors' objectives:
The Assessment summarizes and evaluates evidence on health outcomes of sorafenib and sunitinib for off-label indications reported in published studies or currently undergoing phase III trials. Since these medications overlap only partially with respect to the receptor tyrosine kinases each inhibits, sorafenib and sunitinib were assessed separately.
Details
Project Status:
Completed
URL for project:
http://www.bcbs.com/blueresources/tec/contact-tec.html
Year Published:
2007
English language abstract:
An English language summary is available
Publication Type:
Not Assigned
Country:
United States
MeSH Terms
- Clinical Trials, Phase III as Topic
- Drug Approval
- Female
- Male
- Product Labeling
- Randomized Controlled Trials as Topic
- Treatment Outcome
- United States
- United States Food and Drug Administration
- Adenocarcinoma
- Angiogenesis Inhibitors
- Breast Neoplasms
- Carcinoma, Non-Small-Cell Lung
- Digestive System Neoplasms
- Gastrointestinal Stromal Tumors
- Head and Neck Neoplasms
- Indoles
- Melanoma
- Neoplasms, Squamous Cell
- Pyridines
- Pyrroles
Contact
Organisation Name:
BlueCross BlueShield Association
Contact Address:
BlueCross BlueShield Association, Technology Evaluation Center, 225 North Michigan Ave, Chicago, Illinois, USA. Tel: 888 832 4321
Contact Name:
tec@bcbsa.com
Contact Email:
tec@bcbsa.com
Copyright:
BlueCross BlueShield Association (BCBS)
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.